Manufactures synthetic DNA on a silicon-chip platform, selling genes and DNA libraries to biotech, pharma and diagnostics researchers.
Manufactures synthetic DNA on a silicon-chip platform, selling genes and DNA libraries to biotech, pharma and diagnostics researchers.
Sells synthetic DNA ordered online in many small orders, with revenue split across gene products, tools for preparing samples for sequencing, and antibody discovery services for drug developers. Orders come from a wide base of labs, so no single customer dominates, and most revenue is repeat consumables.
Moat: narrow (IP / patents, process know-how, scale). Proprietary silicon-based DNA synthesis technology enables lower-cost, higher-throughput gene manufacturing.
Headquarters: South San Francisco, California, US · Founded: 2013 · Employees: 1,080
Size Twist Bioscience (TWST) is a United States Health Care company (Biotechnology) with a market value of $7.93B, the 884th largest of 3,085 United States companies the cockpit tracks. Shares closed at $116.35 on 18 Nov 2026.
Performance Over six months the shares gained 116.8%, against +23.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 22.0% over the last twelve months (peer median +26.0%); the operating margin is -28.8% (peer median 10.9%).
Valuation It trades at 16.2× enterprise value to sales against a peer median of 10.5× (7th most expensive of 17).
Capital Return on invested capital runs 42.2 points below its cost of capital (16.2% WACC).
Backlog Backlog (remaining performance obligations) was $21.6M at 30 Sep 2026, up 43% on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 14.9% of the free float (30 Oct 2026).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $459M | $459M | $377M | $313M | $245M |
| Revenue growth | — | +22% | +20% | +28% | — |
| Gross profit | $241M | $241M | $191M | $133M | $89.7M |
| EBITDA | -$106M | -$106M | -$111M | -$144M | -$178M |
| Net income | -$130M | -$130M | -$77.7M | -$209M | -$205M |
| Free cash flow | -$89.0M | -$89.0M | -$75.6M | -$69.2M | -$170M |
| Capital expenditure | $54.5M | $54.5M | $28.0M | $5.08M | $27.8M |
| Total debt | $95.0M | $95.0M | $75.6M | $85.0M | $94.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Twist Bioscience TWST | $7.93B | +117% | +22% | -29% | 16.2× | n/a |
| Danaher DHR | $161B | +34% | +6% | 21% | 7.1× | 20.8% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 6.2× | 21.3% |
| Azenta AZTA | $2.03B | +162% | +5% | -2% | 2.8× | 38.0% |
| Agilent Technologies A | $50.0B | +56% | +9% | 24% | 7.1× | 23.3% |
| Eurofins Scientific ERF.PA | $16.4B | +37% | +3% | 12% | 2.7× | 12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TWST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.5% | -2.6% | 7th lowest of 21 |
| 6-month return | +116.8% | +23.0% | 4th highest of 21 |
| Distance from 52-week high | -47.0% | -27.7% | 5th lowest of 21 |
| Revenue growth (TTM) | +22.0% | +26.0% | 8th lowest of 16 |
| Operating margin | -28.8% | 10.9% | 6th lowest of 17 |
| EV / Sales | 16.2× | 10.5× | 7th most expensive of 17 |
| ROIC minus cost of capital | -42.2 pp | -0.5 pp | 4th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% | +19.8% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 35.1× | 24.6% | +38.5% |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 18.0× | 13.1% | +26.0% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 3.7× | 6.2% | +2.3% |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | 92.4× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 7.3× | -0.3% | +39.2% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 9.2× | 31.6% | +5.5% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 4.2× | 8.2% | +12.0% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
Twist Bioscience reported $21.6M of remaining performance obligations at 30 Sep 2026, up 43% from a year earlier and down 1% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.